PDL BioPharma: which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns PDL BioPharma?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Brandes Investment Partners (13G filed Aug 13, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were Diversified Trust (11,554 shares) and Rhumbline Advisers (612 shares).
Sources:13G by Brandes Investment Partners (Aug 13, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
PDL BioPharma revenue
PDL BioPharma reported annual revenue of $30.7 million for fiscal year 2019 (year ended December 31, 2019), according to its Form 10-K filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders (all 13F filers)
- Diversified Trust12 KWealth adviser0
- Rhumbline Advisers612Index manager0
- Shares
- 12 K
- Change
- 0
See more
- Type
- Wealth adviser
- Value
- $27.7K
- Shares
- 612
- Change
- 0
See more
- Type
- Index manager
- Value
- $1.5K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Brandes Investment Partners6.2%13Gfiling ↗Event: Jun 30, 2026 · filed: Aug 13, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market.